A5059720509- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Economic and Financial Impacts of Cancer
- Palliative Care and End-of-Life Issues
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Cancer survivorship and care
- Neuroendocrine Tumor Research Advances
- Medication Adherence and Compliance
- Health Systems, Economic Evaluations, Quality of Life
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Fibroblast Growth Factor Research
- Cancer Research and Treatments
- Pharmaceutical Practices and Patient Outcomes
- Gastrointestinal Tumor Research and Treatment
- Renal cell carcinoma treatment
- Safe Handling of Antineoplastic Drugs
- Kruppel-like factors research
- Brain Metastases and Treatment
- Lung Cancer Research Studies
- Hepatocellular Carcinoma Treatment and Prognosis
Azienda Unità Sanitaria Locale Piacenza
2023-2025
Guglielmo da Saliceto Hospital
2015-2024
Ospedaliera di Piacenza
2014-2024
Malignant pleural effusion (MPE) is an extremely common problem affecting cancer patients, and thoracentesis essential procedure in attempt to delineate the etiology of fluid collections relieve symptoms affected patients. One most complications pneumothorax, which has been reported occur 20% 39% thoracenteses, with 15% 50% patients pneumothorax requiring tube thoracostomy. The present study was carried out assess whether thoracenteses performed ultrasound (US) guidance are associated a...
Advanced pancreatic cancer has a poor prognosis and 5-year survival rate <5%; thus, treatment of patients with advanced unresectable or metastatic disease is challenging. Current guidelines recommend either gemcitabine plus nab-paclitaxel (GnP) FOLFIRINOX (FOL) as first-line treatment. Data on both efficacy toxicity FOL versus GnP in are limited. This study aimed to compare the two chemotherapy regimens terms real-world setting.
Introduction The phase III Keynote-189 trial established a first-line treatment combining pembrolizumab with pemetrexed and platinum as standard for patients stage IV non-small cell lung cancer (NSCLC) without known EGFR ALK driver mutations independent of programmed death ligand 1 (PD-L1) expression. However, in Italy, eligibility the National Health Service payment program is limited to PD-L1 &lt;50%. PEMBROREAL study assesses real-world effectiveness safety eligible program. Methods...
Results from the phase III Keynote-024 clinical trial established pembrolizumab monotherapy as first-line standard of care for patients with metastatic NSCLC who have PD-L1 expression ≥ 50%, EGFR, and ALK wild-type tumors. However, given differences between treated in routine practice those a trial, real-world data are needed to confirm treatment benefit practice. Given lack on large cohorts long follow-ups, we designed an observational retrospective study were pembrolizumab, starting its...
Traveling to healthcare facilities, particularly in the case of patients requiring frequent visits and repeated treatments, such as cancer patients, is associated with substantial carbon dioxide (CO2) emissions. Moreover, travel burdens can delay diagnosis negatively influence prognosis. In 2004, a programme called territorial oncology care (TOC) was initiated province Piacenza (northern Italy) relieve by providing treatment closer patients' residences. Patient management performed...
Life expectancy, quality of life and satisfaction oncologic patients highly depend on access to adequate specialized services, that consider their conditions in a holistic way. The present study aims evaluate the introduction oncology services an outpatient setting mountain village Northern Italy. initiative is evaluated using three pillars sustainability (social, economic environmental) as dimensions are often overlooked by healthcare policy makers. Using micro data 18,625 interventions, we...
Central nervous system (CNS) metastases from cancers of the gastrointestinal tract (GIT) are rare, and occur in 0.16-0.69% patients with gastric or gastro-esophageal (GE) junction cancer. Overexpression human epidermal growth factor 2 (HER-2) is associated poor prognosis absence HER-2-targeted therapy, an increased incidence CNS breast The role HER-2 overexpression not well known adenocarcinoma. purpose present retrospective study was to assess evaluate associations between status a series...
Results from the phase III Keynote-024 clinical trial have established Pembrolizumab monotherapy as first-line standard of care for patients with metastatic NSCLC who PD-L1 expression ≥ 50%, EGFR and ALK wild-type. However, given differences between treated in routine practice within a trial, real-world data are needed to confirm treatment benefit practice. Given lack on large cohorts long follow-up, we designed retrospective observational study were Pembrolizumab, starting its reimbursement...
Purpose: Metastatic pancreatic adenocarcinoma has a very poor prognosis. Although irinotecan, oxaliplatin and leucovorin-modulated fluorouracil (FOLFIRINOX) significantly increases survival in advanced cancer, compared to employing only gemcitabine (GEM), toxicities have tempered enthusiasm for its use. Methods: This study retrospectively analyses the real-world clinical practice with full attenuated doses of FOLFIRINOX unselected patients locally unresectable or metastatic treated at an...
Background Cancer patients can be a human model of potential drug interactions. Usually they receive large number different medications, including antineoplastic agents, drugs for comorbid illness and medication supportive care, however information about these interactions are fragmented poor. Objective We assessed prospective study to evaluate the prevalence interaction among hospitalized in Onco-Haematology department, Hospital Piacenza. Methods Data on administered cancer, comorbidities,...
Complete clinical response in rectal cancer after neoadjuvant chemo-radiotherapy is challenging. Indeed, indication to surgery vs. "watch and wait" a debate due the poor predictive value of restaging exams order identify pathological complete (pCR). Improving knowledge on mutational pathways such as MAPK/ERK could be helpful assessing real impact disease prognosis choosing best therapeutic target. This study aimed evaluate significance biomolecular parameters prognostic factors patients...
Background and Objectives: The distance to cancer facilities may cause disparities by creating barriers oncologic diagnosis treatment, travel burden time financial toxicity. Materials Methods: To relieve burden, a program deliver treatment closer the patient was initiated in district of Piacenza (Northern Italy) several years ago. activities are performed oncologists nurses who from ward city hospital territorial centres provide management. This model is called Territorial Oncology Care...
Objectives The incidence of pancreatic ductal adenocarcinoma (PDAC) increases with age and is frequently diagnosed at an inoperable stage, which limits treatment options. There limited evidence concerning patients over 75 years old, clinical practice often lacks clear guidance regarding the choice first-line therapy. primary objective this retrospective study was to assess overall survival (OS) in elderly receiving monochemotherapy vs combination Secondary objectives included evaluating...
Little is known about the real impact of COVID-19 outbreak on qualitative and quantitative fall-out management cancer patients. Our objective was to provide evidence effects SARS-COV-2 patients in world.In a general hospital district Italy with high prevalence during first wave, we retrospectively analyzed data oncologic activity, namely new diagnosis, types treatment (intravenous or by mouth), clinical research studies, drug utilization, compared findings those 2019, before pandemic. The...
Background: Cancer trials involving multiple treatment lines substantially increase our understanding of therapeutic strategies. However, even when the primary end-point these studies is progression-free survival (PFS), their statistical analysis usually focuses on each line separately, or does not consider repeated events, thus missing potentially relevant information. Consequently, evaluation effectiveness strategies highly impaired. Methods: We evaluated different effect bevacizumab (B)...
In the field of oncology, we are all stimulated by desire to improve lives patients with cancer; however little data available about amount time and travel discomfort that families typically spend for clinical examinations antitumoral/supportive treatments. The purpose this study was determine advantages cancer receive clinical, test examinations, anticancer treatment near their residence in a territorial structure called "Casa della Salute" (CdS).Since July 2016 treated at Oncology Unit...
Pancreatic cancer is a highly lethal disease, often diagnosed at advanced stages, with 5-year overall survival rate of around 10%. Current treatments have limited effectiveness, underscoring the need for new therapeutic options. This scoping review aims to identify and summarize preclinical clinical studies on FGFR (Fibroblast Growth Factor Receptor) inhibitors, including tyrosine kinase inhibitors (TKIs) FGFR-specific in pancreatic alterations. We included analyzing efficacy, safety,...
The combination of chemotherapy and immunotherapy for metastatic cholangiocarcinoma (CCA) offers promising improvements in survival response rates beyond traditional treatments. TOPAZ-1 KEYNOTE-966 have demonstrated the efficacy combining (durvalumab pembrolizumab) with chemotherapy, even gallbladder cancer (GBC), a complete rate 2.7% trial. Advanced CCA treated combinations has shown responses influenced by high programmed death-ligand 1 (PD-L1) or Epstein-Barr virus expression. These were...
The natural history of cancer has radically changed in the last decade. burden travel from patient's residence to health care providers is an important issue that can influence access diagnosis and treatment cancer; however this quite neglect by medical community national system. In addition, oncology field actually debated.In district Piacenza innovative model deliver onco-hematologic near patients was initiated some years ago. oncologic hematologic treatments are delivered specialized...